Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse

Autor:	Nikolina Dukić, Sladjana Popovic, Nenad Lalovic, Srdjan Masic, Zdenka Gojkovic, Jelena Vladičić-Mašić
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty business.industry medicine.medical_treatment Time to relapse Hematology Trastuzumab HER2 Positive Breast Cancer Internal medicine medicine skin and connective tissue diseases business neoplasms Adjuvant medicine.drug
Zdroj:	Archive of Oncology. 26:10-15
ISSN:	1450-9520 0354-7310
DOI:	10.2298/aoo181112006d
Popis:	Background: Of all breast cancers 20-25% are HER2 positive. Overexpression of HER2 protein on the surface of the malignant cell leads to excessive cell proliferation through different signaling pathways. Trastuzumab is a human monoclonal antibody that binds to domain IV of HER2 receptor and blocks signaling pathway for proliferation. The result is an improved prognosis for HER 2 positive breast cancer patients, even when compared to patients with other types of breast cancers. Methods: The study presents 74 women patients with early HER2 positive breast cancer who were previously operated (either radicaly or using breast conserving surgery), and received adjuvant chemo- and radiotherapy. Fourty four patients received adjuvant trastuzumab for one year, and 30 patients did not (control group). Observed time to relapse of the disease was 60 months. Results: There was a significant difference in survival in favor of the group that received trastuzumab (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b9816bb99d305e3e164cf27b06dfd518 https://doi.org/10.2298/aoo181112006d Zobrazit plný text záznamu